News & Updates

Show Multimedia Only

Multiple skin cancers can occur in treated patients, says study

28 May 2025

A recent study claims that almost half of the patients treated for skin cancer will again develop the disease within 2 years of the first incidence.

Multiple skin cancers can occur in treated patients, says study

28 May 2025

MRD-response-in-two-patients-with-AML-treated-with-oral-maintenance-therapy

28 May 2025 by

A 63-year-old male presented with symptomatic anaemia (haemoglobin [Hb], 2.9 g/dL) and loss of appetite in October 2022. He was an ex-smoker, and had a history of hypertension and hyperlipidaemia, and a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0.

MRD-response-in-two-patients-with-AML-treated-with-oral-maintenance-therapy

28 May 2025

Antiviral therapy lowers HCC risk in indeterminate CHB phase

27 May 2025 by

Patients with chronic hepatitis B (CHB) in the indeterminate phase are predisposed to advanced liver disease and hepatocellular carcinoma (HCC), as shown by a systematic review and meta-analysis.

Antiviral therapy lowers HCC risk in indeterminate CHB phase

27 May 2025

Personalizing upfront treatment options for advanced EGFRm NSCLC

26 May 2025 by

This article will summarize the latest developments in the first-line management of advanced EGFRm NSCLC and highlight key consideration factors.

Personalizing upfront treatment options for advanced EGFRm NSCLC

26 May 2025

No APHINITY between statin use and survival outcomes in early HER2-positive breast cancer

26 May 2025 by

Statin use was not associated with improved survival outcomes in the phase III APHINITY trial investigating the addition of pertuzumab to trastuzumab and chemotherapy as adjuvant treatment for patients with early HER2-positive breast cancer (BC).

No APHINITY between statin use and survival outcomes in early HER2-positive breast cancer

26 May 2025

Next-generation KRASG12C inhibitor monotherapy convenient, shows promising antitumour activity

25 May 2025 by

A multinational phase I study led by the Chinese University of Hong Kong (CUHK) reports an overall objective response rate (ORR) of >70 percent in advanced solid KRAS^G12C-mutant tumours treated with D3S-001, a next-generation KRAS^G12C inhibitor developed in mainland China.

Next-generation KRASG12C inhibitor monotherapy convenient, shows promising antitumour activity

25 May 2025

GLP-1RAs help reduce risk of gastrointestinal cancers

23 May 2025 by

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs), as opposed to insulin or metformin, provides a protective benefit against the development of gastrointestinal cancers, as shown in a study presented at DDW 2025.

GLP-1RAs help reduce risk of gastrointestinal cancers

23 May 2025

Dostarlimab may eliminate the need for surgery in early-stage dMMR tumours

23 May 2025 by

PD-1 blockade with dostarlimab may eliminate the need for surgery in patients with early-stage mismatch repair–deficient (dMMR) solid tumours amenable to curative intent surgery, a phase II trial has shown.

Dostarlimab may eliminate the need for surgery in early-stage dMMR tumours

23 May 2025

Ageing-related diseases occur early among childhood cancer survivors

23 May 2025

Survivors of childhood cancer undergo accelerated ageing, with a recent study showing a 2-decade earlier onset and a greater lifetime risk of common and life-threatening chronic health conditions (CHCs).

Ageing-related diseases occur early among childhood cancer survivors

23 May 2025

Survival benefits of trastuzumab deruxtecan in patients with previously treated HER2-low mBC

22 May 2025 by

The therapeutic landscape of HER2-low metastatic breast cancer (mBC) has been transformed by the availability of trastuzumab deruxtecan (T-DXd; Enhertu^®, Daiichi Sankyo & AstraZeneca), an antibody-drug conjugate (ADC). At a recent Hong Kong Breast Cancer Foundation (HKBCF) Academic Meeting, Dr Shanu Modi of Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, US, discussed the efficacy and safety of T-DXd in the phase III DESTINY-Breast04 trial. Local experiences with T-DXd were shared by Dr Roland Leung of the Department of Medicine, the University of Hong Kong.

Survival benefits of trastuzumab deruxtecan in patients with previously treated HER2-low mBC

22 May 2025

News & Updates

Filter by Specialty:

Specialty:

Multiple skin cancers can occur in treated patients, says study

Multiple skin cancers can occur in treated patients, says study

MRD-response-in-two-patients-with-AML-treated-with-oral-maintenance-therapy

MRD-response-in-two-patients-with-AML-treated-with-oral-maintenance-therapy

Antiviral therapy lowers HCC risk in indeterminate CHB phase

Antiviral therapy lowers HCC risk in indeterminate CHB phase

Personalizing upfront treatment options for advanced EGFRm NSCLC

Personalizing upfront treatment options for advanced EGFRm NSCLC

No APHINITY between statin use and survival outcomes in early HER2-positive breast cancer

No APHINITY between statin use and survival outcomes in early HER2-positive breast cancer

Next-generation KRASG12C inhibitor monotherapy convenient, shows promising antitumour activity

Next-generation KRASG12C inhibitor monotherapy convenient, shows promising antitumour activity

GLP-1RAs help reduce risk of gastrointestinal cancers

GLP-1RAs help reduce risk of gastrointestinal cancers

Dostarlimab may eliminate the need for surgery in early-stage dMMR tumours

Dostarlimab may eliminate the need for surgery in early-stage dMMR tumours

Ageing-related diseases occur early among childhood cancer survivors

Ageing-related diseases occur early among childhood cancer survivors

Survival benefits of trastuzumab deruxtecan in patients with previously treated HER2-low mBC

Survival benefits of trastuzumab deruxtecan in patients with previously treated HER2-low mBC